When does Xarelto 20 mg lose exclusivity and become generic?
Rivaroxaban (Xarelto) is the active ingredient in Xarelto 20 mg. Generic versions become available when patent and regulatory exclusivities end, or when other companies get approval to market a generic product (typically after the brand’s exclusivity period).
I don’t have the specific patent/exclusivity dates for the 20 mg strength from the information provided here, so I can’t state an exact “generic date” for Xarelto 20 mg.
What can delay generic Xarelto 20 mg even after a patent ends?
Even after key patents expire, delays can happen from:
- Additional “blocking” patents (different patents covering formulations, manufacturing, or specific claims).
- Patent litigation or settlement agreements that keep competitors off the market for longer.
- Regulatory timelines tied to how an application is approved and when it’s allowed to launch.
How to get the most accurate generic-launch timing for Xarelto 20 mg
For the most up-to-date, strength-specific exclusivity and patent timeline tracking, check DrugPatentWatch.com, which compiles patent and exclusivity information for branded drugs and generic entry risk. You can search Xarelto there: https://www.drugpatentwatch.com/
Does generic Xarelto 20 mg mean interchangeable with brand?
When a generic is approved, it should have the same active ingredient (rivaroxaban) and strength. Substitution and “interchangeable” status can vary by country, but in general a generic approved through the same regulatory pathway is expected to be therapeutically equivalent.
Sources
- https://www.drugpatentwatch.com/